Daily Stock Opinions and Ratings

Latest Stock Buy or Sell? Make More Informed Decisions!

Today, Ross Healy and Paul MacDonald commented about whether AMGN-Q, BMY-N, UNH-N, SNY-N, DGX-N, BSX-N, GILD-Q, MDT-N, TEVA-N, GSK-N, IBB-Q, SYK-N, MRK-N, CELG-Q, LLY-N, BIIB-Q, ABBV-N, PFE-N, REGN-Q, CASH, HUV-T, CVS-N, LNR-T, MFI-T, AEM-T, PM-N, BABA-N, TD-T, HCG-T, AGN-N, ABX-T, BNS-T, ACO.X-T, WCN-T, MSFT-Q, OSB-T, VET-T, CM-T, NFLX-Q, GOOG-Q, AAPL-Q, AMZN-Q, META-Q, NVDA-Q are stocks to buy or sell.

Page 2/4

PAST TOP PICK

(A Top Pick Jun 04/18, Up 3%) He likes the gold stocks because you should always hold 10-20% in gold. Bullion is dirt cheap. He worries about the quality of balance sheets around the world and sees it as a safe haven.

HOLD

Hold onto this stock. Even though the balance sheet is not great, there is a good chance their aggressive earnings outlook will drag the stock back up. It is extremely cheap at these levels.

HOLD

It is very cheap right now. There is 180% potential upside, if you believe analysts earnings forecast. They need to use their earnings to pay a dividend. This would give the signal that management is under control again.

HOLD

It hit a nice bottom recently around $68. It has nice upside potential and a decent dividend. Management quality is great and leads the way in customer satisfaction. They seem to be able to avoid tough issues.

HOLD

High risk? It is not exactly cheap trading at 6.5 times book value. Compared to Amazon at 18 times book, it looks safer. It is not the cheapest stock, but it has value up to $215. Maybe if there was less concern about China in general.

DON'T BUY

It has a great dividend. The balance sheet has gone no where and the fair market value is 35% below current levels. Very, very expensive. Cigarettes will remain around a long time, but it is not the kind of stock that would let him sleep well at night. It is trading at 82 times book value -- way too risky. Their big share buy back might backfire in that the there may not be enough liquidity to create support in time of trouble.

HOLD

Junior gold producers? The best values in gold are the juniors -- especially if we get a good rally in gold again. He does hold AEM-T, but thinks the real gems are the juniors.

HOLD

MFI-T stock price has followed its fair market value -- currently $33 -- likely a ceiling for now. He needs to see earnings improving to get bullish.

DON'T BUY

It is so cheap at these levels. It has a decent balance sheet, but trades at 5 times earnings. The problem is auto sales are heading lower globally, he thinks. If you have patience sit tight, but he is loath to get in front of a freight train coming out of the tunnel -- lots of light, but don't get run over.

TOP PICK

The stock is very cheap, trading down to book value -- historically a great buy. It bought Aetna and a lot of goodwill. He applies a test on the return on equity and if it is above 10%, then the goodwill is of good value. CVS-N has a ROE of 14%. Yield 3.52%. (Analysts’ price target is $71.69)

TOP PICK

He thinks this could soar if stock values go down. The VIX ETF for market volatility is suggesting investors think this market is going up forever. This is a contrarian trade. Do not hold this for a year, it is a trade.

TOP PICK

He thinks you should hold higher levels of cash. You should have about 10-20% weighting here now.

COMMENT

Stock market buoyancy today. Market of two tales. Any correction in growth names, like tech and consumer discretionary, tends to get bought. Good numbers are coming in. Defensives like healthcare and utilities are a different story.

COMMENT

Golden opportunity to get into healthcare? Positives are there such as aging population, developing markets, new technologies set the stage for long-term positive dynamics. In the shorter term, polarized extreme views have come out, but there's no substance to them. The correction is just noise, and it's a well-timed entry point in the sector. Bernie Sanders' "medicare for all" inspired a downturn. Technical healthcare names have held up.

BUY

Diversity is key. Large biotech has been beat up. Speculation that Novartis is a competitor, but it's at early stages for them. REGN does have a drug for a niche market. Correction is in part because of Novartis speculation plus medicare reimbursement. Current multiple around 13x, you can buy it, but buy it in a basket.

Most Recent Experts

Colin Stewart

JC Clark Investments Ltd.

Stockchase Insights

5i Research

Jim Cramer - Mad Money

CNBC

Bill Harris, CFA

Avenue Investment Management

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Latest Stock Buy or Sell? Make More Informed Decisions!

Barrick Mining(ABX-T)

Allergan PLC.(AGN-N)

Home Capital Group(HCG-T)

Toronto Dominion(TD-T)

Alibaba Group Holding(BABA-N)

Philip Morris International(PM-N)

Agnico-Eagle Mines(AEM-T)

Maple Leaf Foods(MFI-T)

Linamar Corp(LNR-T)

CVS Health Corp(CVS-N)

HBP S&P500 VIX Short Term VIX ETF(HUV-T)

CASH(CASH)

Stock market buoyancy today.(A Commentary)

Golden opportunity to get into healthcare?(A Commentary)

Regeneron Pharmaceuticals Inc(REGN-Q)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Colin Stewart

Stockchase Insights

Jim Cramer - Mad Money

Bill Harris, CFA

The Panic-Proof Portfolio (Stockchase Research)